Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases

Modern Pathology

Volumn 13, Issue 8, 2000, Pages 841-850

  Briffod, Marianne ^a   Hacène, Kamel ^a   Le Doussal, Viviane ^a  

^a CENTRE RENÉ HUGUENIN   (France)

Author keywords

Breast cancer; Cell block; Fine needle cytopuncture; Immunohistochemistry; Lymph node metastasis

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53;

ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REPRODUCIBILITY;

EID: 0033902805     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880149     Document Type: Article

References (43)

1. Fine-needle aspiration technique for the concurrent immunocytochemical evaluation of multiple biologic parameters in primary breast carcinoma
2. Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma
3. Cytological evaluation of biological prognostic markers from primary breast carcinomas
4. Assessing estrogen and progesterone receptor status in fine-needle aspirates from breast carcinomas. Results on six years of material and correlation with biochemical assay
5. Semiquantitative assessment of c-erbB-2 (HER-2) status in cytology specimens and tissue sections from breast carcinoma
6. The assessment of multiple variables on breast carcinoma fine needle aspiration (FNA) cytology specimens: Method, preliminary results and prognostic associations
7. Cytologic nuclear grading of fine-needle cytopunctures of breast carcinoma: Comparison with histologic nuclear grading (MSBR) and image cytometric data
8. Immunocytochemical staining for the c-erbB-2 gene product in breast aspirates: A preliminary report
9. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy
10. p53 Protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
11. p53 Immunohistochemical analysis in breast cancer with four monoclonal antibodies: Comparison of staining and PCR-SSCP results
12. Comparison of quantitative and semi-quantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma
13. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
14. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer
15. Prognostic value of immunohistochemical expression of p53 in breast carcinomas. A review of the literature involving over 9,000 patients
16. Prognostic value of p53 in breast invasive ductal carcinoma: An immunohistochemical study on 942 cases
17. p53 Mediated tumor cell response to chemotherapeutic DNA damage. A preliminary study in matched pairs of breast cancer biopsies
18. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients
19. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers
20. Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis?
21. The HER-2/neu oncogene in breast cancer. Prognostic factor, predictive factor, and target for therapy
22. Correlation of cerbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
23. Use of monoclonal antiestrogen receptor antibody to evaluate estrogen receptor content in fine needle aspiration breast biopsies
24. Use of monoclonal antibody for assessment of estrogen receptor content in fine-needle aspiration biopsy specimen from patients with breast cancer
25. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer
26. Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients
27. Long-term prognostic impact of immunohistochemical estrogen receptor determinations compared with biochemical receptor determination in primary breast cancer
28. Recommandations pour l'evaluation immunohistochimiques des recepteurs hormonaux sur coupes en paraffine dans les carcinomes mammaires
29. Variations of hormonal receptor, pS2, C-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: A study of 74 cases
30. Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies
31. Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas
32. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer
33. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma
34. DNA index and cell cycle analysis of primary breast cancer and synchronous axillary lymph node metastases
35. Tumor labeling indices of primary breast cancers and their regional lymph node metastases
36. Evidence for limited molecular genetic heterogeneity as defined by allelotyping and clonal analysis in nine metastatic breast carcinomas
37. Heterogeneity for allelic loss in human breast cancer
38. Genetic alterations in primary breast cancers and their metastases: Direct comparison using modified comparative genomic hybridization
39. p53 In breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (Ki-67) and c-erbB-2. Immunohistochemical study of 153 cases
40. Accumulation of p53 suppressor gene protein: An independent marker of prognosis in breast cancers
41. Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: Retrospective follow-up study of 245 stage I and II cases
42. Prognostic impact of proliferation-associated factors MIB1 (Ki67) and S-phase in node-negative breast cancer
43. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer